Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Atox Bio Publishes Data Demonstrating the Broad Therapeutic Effect of AB103

Published: Monday, April 15, 2013
Last Updated: Monday, April 15, 2013
Bookmark and Share
Findings published in the Journal of Infectious Diseases.

Atox Bio has announced new data in an animal model of necrotizing soft tissue infection (NSTI), commonly known as “flesh eating bacteria” demonstrating that administration of a single dose of AB103, given several hours after infection even without any antibiotics, increased survival in animals, and reduced tissue necrosis, inflammation and bacterial burden at the site of infection without compromising the immune response.

NSTI or flesh eating bacteria is a life-threatening bacterial infection with significant morbidity and no currently approved therapies.

These finding are significant as they suggest that AB103 has a broad therapeutic window and could be used even in cases of antibiotic ineffectiveness such as with antibiotic resistant bacteria.

The data were published in a paper titled “A peptide antagonist of CD28 signaling attenuates toxic shock and necrotizing soft tissue infection induced by Streptococcus pyogenes” that was published in the March issue of the Journal of Infectious Diseases.

This new research supports the positive results obtained in the recently completed Phase 2a clinical trial with AB103 in 40 patients with NSTI conducted at 6 leading medical centers across the U.S.

The randomized, double-blind, placebo-controlled study demonstrated that patients treated with AB103 had a meaningful improvement across multiple endpoints in NSTI caused by different types of pathogens, including gram positive bacteria, gram negative bacteria and mixed infections.

Patients treated with AB103 had a faster resolution of organ dysfunction, spent fewer days in the intensive care unit, required fewer days of assisted ventilation and needed fewer surgical procedures to remove infected tissue.

AB103 has received an orphan drug status from the FDA in October 2011 and a fast track status in August 2012.

Alan S. Cross, M.D., Professor of Medicine at University of Maryland in Baltimore, Center for Vaccine Development, and the Paper’s lead co-author, stated, "The results with AB103 are impressive. Unlike the case with other agents assessed in animal models, AB103 is highly effective even when given several hours after infection."

Raymond Kaempfer, Ph.D., Professor of molecular biology and cancer research at the Faculty of Medicine of The Hebrew University of Jerusalem, Israel, Atox Bio’s Chief Scientist and the Paper’s second lead co-author, said, "Our insight into how an excessive inflammatory response is generated via the newly identified bottleneck of the CD28 co-stimulatory receptor, now allows for more effective treatment of live bacterial infection."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Atox Bio Closes $23 Million Investment
Funds will be used to advance development of AB103, a novel therapy for the treatment of necrotizing soft tissue infections.
Friday, July 25, 2014
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Kitchen Utensils Can Spread Bacteria Between Foods
In a recent study researchers found that produce that contained bacteria would contaminate other produce items through the continued use of knives or graters—the bacteria would latch on to the utensils commonly found in consumers' homes and spread to the next item.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Safer, Faster Way To Remove Pollutants From Water
Using nanoparticles filled with enzymes proves more effective than current methods.
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Novel Tumor Treatment
In the first published results from a $386,000 National Cancer Institute grant awarded earlier this year, a paper by Scott Verbridge and Rafael Davalos has been published.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
New Analysis Technique for Chiral Activity in Molecules
Professor Hyunwoo Kim of the Chemistry Department and his research team have developed a technique that can easily analyze the optical activity of charged compounds by using nuclear magnetic resonance (NMR) spectroscopy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos